Phase III trial of Xiaflex finds benefits for Dupuytren's Contracture

Data from multiple trials evaluating the use of Xiaflex/Xiapex (collagenase clostridium histolyticum), from Auxilium Pharma and SOBI, in adult patients with Dupuytren's Contracture with a palpable cord were presented at the 68th Annual Meeting of the American Society for Surgery of the Hand. Data from CORDLESS, a five-year observational study, indicated that 57.9 percent of patients previously successfully treated with Xiaflex did not experience disease recurrence based on the study's definition of recurrence, which is a 20 degree change of contracture with a palpable cord, or the joint undergoing medical or surgical intervention.

Of the 623 joints assessed, only 12.8 percent of those joints received medical or surgical intervention through Year 4 and of these patients, most were retreated with Xiaflex. The data also reveal no new long-term adverse events.